We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Defective Cell Extrusion May Lead to Formation of Tumors in Pancreas, Lungs, or Colon

By LabMedica International staff writers
Posted on 09 Feb 2015
The disruption of normal S1P2 (sphingosine-1-phosphate receptor 2) receptor activity in epithelial cells prevents the pro-apoptotic extrusion of cells from overcrowded tissue and leads to the formation of cancerous growths in the pancreas, lung, and colon.

When epithelial tissues become too crowded, some cells are extruded that later die. More...
To extrude, a cell produces the lipid, sphingosine 1-phosphate (S1P), which activates S1P2 receptors in neighboring cells that seamlessly squeeze the cell out of the epithelium. Tumors or epithelia lacking S1P2 cannot extrude cells in the normal fashion, which can contribute to carcinogenesis and tumor progression.

Investigators at the University of Utah (Salt Lake City, USA) studied the extrusion process in a zebrafish model system. They reported in the January 26, 2015, online edition of the journal eLife that when S1P2 signaling was disrupted, cells built up and formed masses that resisted apoptosis—even when it was triggered by chemotherapy—or they slipped into underlying tissues where they could potentially begin to grow. Furthermore, some cells died without being extruded, creating poor barrier function in the epithelium, which could cause chronic inflammation.

Inducing S1P2 expression was found to be sufficient to restore extrusion and cell death and reduced pancreatic tumors and their metastases. An inhibitor of the enzyme FAK (focal adhesion kinase) was found to enable cells to bypass extrusion defects and could, therefore, target pancreatic, lung, and colon tumors that lacked S1P2 without affecting normal tissues.

"This kind of altered extrusion may be a common hallmark of invasive tumor types," said senior author Dr. Jody Rosenblatt, associate professor of oncological sciences at the University of Utah. "While the mechanisms that drive tumor cell invasion are not yet clear, the results suggest that S1P2-mediated extrusion may play an important role in metastatic cell invasion. Some FAK inhibitors are already being tested in clinical trials for other types of cancers. Hopefully, they may also be a better therapy for recalcitrant tumors such as pancreas cancers and some lung cancers."

Related Links:

University of Utah



New
Gold Member
Hematology Analyzer
Medonic M32B
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.